MARKET

CKPT

CKPT

Checkpoint Therapeutics
NASDAQ
4.070
+0.010
+0.25%
After Hours: 4.070 0 0.00% 17:00 03/21 EDT
OPEN
4.050
PREV CLOSE
4.060
HIGH
4.070
LOW
4.050
VOLUME
980.43K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.380
MARKET CAP
198.75M
P/E (TTM)
-2.8315
1D
5D
1M
3M
1Y
5Y
1D
Durable Goods, Home Sales in U.S. Due Next Week
Barchart · 2d ago
Checkpoint Therapeutics Inc <CKPT.OQ> expected to post a loss of 19 cents a share - Earnings Preview
Reuters · 5d ago
Weekly Report: what happened at CKPT last week (0310-0314)?
Weekly Report · 6d ago
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
Barchart · 03/14 10:17
This Lennar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 03/11 13:14
Checkpoint Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 03/11 10:50
Checkpoint Therapeutics Price Target Announced at $4.10/Share by HC Wainwright & Co.
Dow Jones · 03/11 10:50
HC Wainwright & Co. Downgrades Checkpoint Therapeutics to Neutral, Announces $4.1 Price Target
Benzinga · 03/11 10:39
More
About CKPT
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

Webull offers Checkpoint Therapeutics Inc stock information, including NASDAQ: CKPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CKPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CKPT stock methods without spending real money on the virtual paper trading platform.